Versatope is developing an innovative universal influenza vaccine (VT-105) that protects animal models against disease and death from diverse pandemic strains. The superiority of VT-105 lies within the technology platform, the potency of the vesicles and genetic engineering to ensure broad-strain protection. We have built upon our success with VT-1... Read more
Versatope’s technology also has the potential to leverage its synthetic biology for additional unmet needs in health care including non-viral gene editing, allergy, immunology, oncology, inflammatory bowel disease, topicals, drug delivery, veterinary diseases and more. Multiple discussions with potential partners are ongoing to leverage the technol... Read more